Herceptin is named as an intervention in 26 current clinical trials in our France, Spain, Italy, Germany, South Korea, Taiwan, UK, China, Belgium, Portugal, Canada, Japan, Australia, USA, Brazil, Mexico, Netherlands, Poland, Austria, Israel, Singapore, Switzerland, Czechia, Ireland, India, Turkey, Norway, Denmark and Sweden registers. 8 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Seagen, a wholly owned subsidiary of Pfizer (2). The most-studied condition is Breast Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Breast Cancer | 10 |
| Breast Cancer, Metastatic | 2 |
| Breast Neoplasms | 2 |
| HER-2 Positive Breast Cancer | 2 |
| HER2-positive Breast Cancer | 2 |
| Gastric Neoplasms | 1 |
| Gastroesophageal Adenocarcinoma | 1 |
| Esophageal Adenocarcinoma | 1 |
| Colorectal Neoplasms | 1 |
| Gastric Cancer | 1 |
| Gastroesophageal Junction Adenocarcinoma | 1 |
| Gastric Adenocarcinoma | 1 |
| HER2 Positive Breast Cancer | 1 |
| Neoplasm Metastasis | 1 |
| Malignant Neoplasm of Breast | 1 |
| Breast Cancer Early Stage Breast Cancer (Stage 1-3) | 1 |
| Invasive Breast Cancer | 1 |
| Estrogen Receptor Positive Breast Cancer | 1 |
| Metastatic Breast Cancer ( HER2 Negative) | 1 |
| Unresectable Breast Cancer | 1 |
| Advanced Breast Cancer | 1 |
| Heart Failure | 1 |
| Anatomic Stage I Breast Cancer AJCC v8 | 1 |
| Anatomic Stage II Breast Cancer AJCC v8 | 1 |
| Early Stage HER2+ Breast Cancer | 1 |
| HER2 + Breast Cancer | 1 |
| Breast Diseases | 1 |
| Stage II Breast Cancer | 1 |
| Stage III Breast Cancer | 1 |
+ 8 more sponsors in the trial list above.
A trial with sites in more than one country appears in each of those registers.
26 current trials in our France, Spain, Italy, Germany, South Korea, Taiwan, UK, China, Belgium, Portugal, Canada, Japan, Australia, USA, Brazil, Mexico, Netherlands, Poland, Austria, Israel, Singapore, Switzerland, Czechia, Ireland, India, Turkey, Norway, Denmark and Sweden registers name Herceptin as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 8 of the 26 trials are recruiting: 3 with sites in France, 2 with sites in Spain, 2 with sites in Italy, 1 with sites in Germany, 2 with sites in South Korea, 1 with sites in Taiwan, 2 with sites in UK, 2 with sites in China, 1 with sites in Belgium, 1 with sites in Portugal, 3 with sites in Canada, 1 with sites in Japan, 1 with sites in Australia, 2 with sites in USA, 2 with sites in Brazil, 1 with sites in Mexico, 2 with sites in Netherlands, 1 with sites in Poland, 1 with sites in Austria, 1 with sites in Singapore, 1 with sites in Switzerland, 1 with sites in Ireland, 1 with sites in Norway and 1 with sites in Sweden. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Seagen, a wholly owned subsidiary of Pfizer (2), ALX Oncology Inc (2), Dana-Farber Cancer Institute (2) and Jazz Pharmaceuticals (1), among 23 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Yes. 2 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Herceptin works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Herceptin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Herceptin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.